Welcome to our dedicated page for Alector SEC filings (Ticker: ALEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alector, Inc. filings document a Nasdaq-listed biotechnology issuer developing therapies for neurodegenerative diseases and reporting progress across the Alector Brain Carrier (ABC) platform. Its 8-K reports include operating and financial results, clinical and portfolio updates, material agreements, and officer appointments.
Regulatory documents also cover the company’s common stock, shelf registration statement and at-the-market equity sales agreement, along with governance matters in proxy materials such as board elections, executive compensation and shareholder voting items. Clinical disclosures address programs in Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia and related neurological disorders, while event filings frame capital resources, platform development, trial outcomes and pipeline changes.
Insider transaction: On 06/20/2025, Alector, Inc. (ALEC) director Kristine Yaffe sold 1,000 shares of common stock at a price of $1.44 per share, according to a Form 4 filed with the SEC.
Following the sale, Yaffe’s direct beneficial ownership stands at 95,409 shares. No derivative security activity was reported, and the filing was signed on 06/23/2025 by attorney-in-fact Danielle Pasqualone.